Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 2016European Heart Journal SupplementsOpen Access

Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does once-daily dosing with non-vitamin K antagonist oral anticoagulants improve medication adherence and stroke prevention in patients with atrial fibrillation?

Population

Patients with atrial fibrillation at moderate to high risk of stroke

Comparison

Once-daily dosing with non-vitamin K antagonist… vs Vitamin K antagonists or more complex dosing…

Design

Review

Authors

WAW. AmaraSASotiris Antoniou

Discussion

Loading...

Member takes

Overview

May support once-daily NOAC regimens to enhance adherence in AF; leaves open confirmation of stroke prevention benefits.

Key Points

  • The aim is to evaluate the benefits of once-daily dosing of non-VKA oral anticoagulants in patients with atrial fibrillation for stroke prevention and adherence.
  • Evaluation of adherence levels to anticoagulants in real-world atrial fibrillation patients.
  • Comparison of once-daily dosing schedules versus traditional anticoagulant regimens.
  • Once-daily dosing improved medication adherence compared to traditional regimens.
  • Improved adherence is associated with better rates of stroke prevention.

Structured PICO

Does once-daily dosing with non-vitamin K antagonist oral anticoagulants improve medication adherence and stroke prevention in patients with atrial fibrillation?

P
Population
Patients with atrial fibrillation at moderate to high risk of stroke
I
Intervention
Once-daily dosing with non-vitamin K antagonist oral anticoagulants
C
Comparator
Vitamin K antagonists (e.g., warfarin) or more complex dosing schedules
O
Outcome
Medication adherence and stroke prevention

Once-daily dosing of non-vitamin K antagonist oral anticoagulants may improve medication adherence and consequently stroke prevention in patients with atrial fibrillation.

Cite This Study

Amara et al. (2016) studied this question.

synapsesocial.com/papers/6a20745355fc9dbe7378051ehttps://doi.org/10.1093/eurheartj/suv062
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients2014 · 186 citations
  2. 2Drug persistence with rivaroxaban therapy in atrial fibrillation patients--results from the Dresden non-interventional oral anticoagulation registry2015 · 144 citations
  3. 3Dabigatran versus Warfarin in Patients with Atrial Fibrillation2009 · 11,272 citations
  4. 4Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.1991 · 7,522 citations
  5. 5Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy2009 · 104 citations